Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6710060 | 0.98 | ESR1 (0.49) | ESR1ESR2DPP4CA12CA1 | |
| SCHEMBL6711049 | 0.84 | ESR1 (0.56) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL6711210 | 0.81 | ESR1 (0.49) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL2478804 | 0.79 | ESR1 (0.46) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL6713974 | 0.78 | ESR1 (0.49) | ESR1ESR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL6712700 | 0.78 | ESR1 (0.45) | ESR1ESR2LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6710202 | 0.78 | ESR1 (0.45) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL2479131 | 0.75 | PKM (0.46) | ESR1ESR2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL8508112 | 0.75 | ESR1 (0.43) | ESR1ESR2DPP4CA12CA1 | |
| SCHEMBL6712589 | 0.75 | MAPT (0.47) | ESR1ESR2LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637551-B2 | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-28 | — | — | US | claimed |
| EP-2473489-B1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-08-21 | — | — | EP | claimed |
| US-20130023566-A1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | N.V. ORGANON (NL) | 2013-01-24 | — | — | US | claimed |
| EP-2473489-A1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | MSD Oss B.V. (NL) | 2012-07-11 | — | — | EP | claimed |
| WO-2011003895-A1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | N.V. ORGANON (NL) | 2011-01-13 | — | — | WO | claimed |
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | claimed |
| CN-1139580-C | Substituted benzylamines and their use for the treatment of depression | ��˹��ŵ�� | 2004-02-25 | — | — | CN | claimed |
| EP-0898566-B1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL NV (NL) | 2002-11-06 | — | — | EP | claimed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | claimed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | claimed |
| CN-1219169-A | Substituted benzylamines and their use for the treatment of depression | AKZO NOBEL NV (NL) | 1999-06-09 | — | — | CN | claimed |
| EP-0898566-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | Akzo Nobel N.V. (NL) | 1999-03-03 | — | — | EP | claimed |
| WO-1997040027-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL N.V. (NL) | 1997-10-30 | — | — | WO | claimed |
| US-8637551-B2 | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-28 | — | — | US | disclosed |
| US-8637551-B2 | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-28 | — | — | US | disclosed |
| US-8637551-B2 | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-28 | — | — | US | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| CN-1219169-A | Substituted benzylamines and their use for the treatment of depression | AKZO NOBEL NV (NL) | 1999-06-09 | — | — | CN | disclosed |
| EP-0898566-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | Akzo Nobel N.V. (NL) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040027-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL N.V. (NL) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023566-A1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | CNR2, CNR1, OPRL1 | ESR1 2795/4885ESR2 1559/4885DPP4 1439/4885 |
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | ESR1 2865/4885ESR2 1589/4885DPP4 469/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | ESR1 2865/4885ESR2 1589/4885DPP4 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.